Regulatory News:
The Combined Ordinary and Extraordinary General Meeting of
Transgene’s (Paris:TNG) shareholders was held today (May 25, 2022)
at 10:00 a.m. at the Company’s headquarters (400 boulevard Gonthier
d’Andernach – Parc d’Innovation – 67400 Illkirch-Graffenstaden,
France).
The meeting was chaired by Hedi Ben Brahim, CEO, to approve the
Company’s financial statements for the year ended December 31,
2021, and to vote on the other resolutions submitted for
approval.
The replay of the Combined General Meeting is available via
Transgene’s website and here.
The Combined General Meeting adopted all resolutions recommended
by the Board of Directors, including notably:
- Appointment of three new Directors:
- Dr. Alessandro Riva, MD, and Prof. Jean-Yves Blay, MD, PhD, as
independent Directors, and
- Laurence Espinasse as non-independent Director;
- Renewal of the following Board Members mandates: Hedi Ben
Brahim and Jean-Luc Bélingard as non-independent Directors;
- Appointment of a new Statutory Auditor, KPMG and renewal of
Grant Thornton.
Following the Combined General Meeting, the Board of Directors
agreed on the following:
- Separation of the roles of Chairman and Chief Executive
Officer, appointing Dr. Alessandro Riva, MD, as independent
Chairman of the Board, alongside Hedi Ben Brahim who continues as
Chief Executive Officer;
- Establishment of an Environmental, Social and Governance (ESG)
committee comprised of Sandrine Flory (committee Chair), Marie
Landel and Hedi Ben Brahim. This new committee aims to enhance the
Company’s ESG performance and reinforce sustainability in the
Company’s strategy.
Hedi Ben Brahim, Transgene’s CEO, commented: “I’m
pleased that the separation of the roles of Chairman and CEO,
leading to the appointment of Dr. Riva as independent Chairman, has
been approved. I’m convinced that this evolution will strengthen
our corporate governance and will be a key further step to
accelerate the development of new solutions for cancer patients. In
addition, I’m proud to announce the establishment of an ESG
committee which further demonstrates our commitment to advance the
Environmental, Social and Governance aspects of our business. In
today’s world, we need to make sure that we continually improve our
ESG commitment. By interacting with Transgene’s in-house ESG
working group, this Board committee will support our sustainable
and long-term strategy, reaffirming our commitment to creating
sustainable value for all our stakeholders.”
Dr. Alessandro Riva, Transgene’s Chairman, added: “I’m
delighted to be joining Transgene, an increasingly important player
in the oncology space as the Company prepares for the next key
steps in its evolution. Internationalization is key in this sector,
and I will be particularly keen to work with our teams to reinforce
the synergies between our activities in Europe and in the USA,
whether they are strategic, operational, or cultural.”
Transgene’s Board of Directors is now comprised of the following
members:
- Dr. Alessandro Riva, Chairman (independent);
- Hedi Ben Brahim, CEO;
- Alain Mérieux, Honorary Chairman;
- Philippe Archinard, Director;
- Jean-Luc Bélingard, Director;
- Prof. Jean-Yves Blay, independent Director;
- Laurence Espinasse, Director;
- Sandrine Flory, Director (TSGH representative);
- Benoît Habert, independent Director;
- Marie Landel, independent Director;
- Maya Saïd, independent Director.
Prof. Jean-Yves Blay’s ability to pursue his mandate is
dependent on the authorization of the public authority to which he
reports.
Detailed voting results are available on Transgene’s website,
under the heading Investors > General Meeting.
Dr. Alessandro Riva, MD, independent Director and
non-executive Chairman
Dr. Riva has nearly 30 years’ experience in the Life Sciences
industry and is currently CEO of Intima Bioscience which
specializes in cell therapies for solid cancers. Prior to this
role, he served as CEO of Ichnos Sciences and Executive Vice
President (EVP), Global Head of Oncology Therapeutics and Cell
& Gene Therapy at Gilead Sciences, where he was instrumental in
the acquisition of Kite Pharma and led its integration and growth.
He also managed the US and EU approvals of Yescarta, the first
approved CAR-T cell therapy for adult patients with diffuse large B
cell lymphoma. Prior to Gilead, Dr. Riva was EVP, Global Head of
Oncology Development and Medical Affairs at Novartis
Pharmaceuticals. He was President ad interim of Novartis Oncology
during the acquisition of GSK Oncology. Dr. Riva currently serves
on the Boards of Beigene and Century Therapeutics. He received his
bachelor’s degree in medicine and surgery from the University of
Milan and a certificate board in oncology and hematology from the
same institution.
Prof. Jean-Yves Blay, MD, PhD, independent Director
Jean-Yves Blay is Professor of Medical Oncology and has been
General Director of the Léon Bérard Center in Lyon since 2014. He
holds a PhD obtained in 1994 from the Claude Bernard University in
Lyon and has been authorized to supervise research since 1996. He
currently leads the LYriCAN project (integrated cancer research) at
the French National Cancer Institute. Former president of the
European Organization for Research and Treatment of Cancer, Prof.
Jean‑Yves Blay is currently director of the NETSARC network
accredited by the French National Cancer Institute and president of
the French Sarcoma Group. At international level, he is a faculty
member of the ESMO (European Society of Medical Oncology) and the
SPH (Scientific Panel for Health). He has led the European
Commission's Conticanet network and is currently leading the
Eurosarc FP7 project. Author of more than 500 international
publications, Prof. Jean-Yves Blay advises various national and
international research organizations and institutions. His work has
been rewarded by several prizes including that of the French
National Academy of Medicine, which he joined as a corresponding
member in 2014.
Laurence Espinasse, Director
Laurence Espinasse has been the Legal Director of Institut
Mérieux since 2021. She practiced as a lawyer for more than 15
years in the law firm MDL, of which she was a partner. Laurence
Espinasse also practiced at Ernst & Young where she was
involved in complex legal transactions, such as M&A and
Restructuring, and was appointed Mission Director from 2012 to
2013. Laurence Espinasse obtained her Professional Lawyer’s
Certificate (Business Law) at the École des avocats Centre Sud
(Montpellier, France).
***
About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on
designing and developing targeted immunotherapies for the treatment
of cancer. Transgene’s programs utilize viral vector technology
with the goal of indirectly or directly killing cancer cells.
The Company’s clinical-stage programs consist of two therapeutic
vaccines (TG4001 for the treatment of HPV-positive cancers, and
TG4050, the first individualized therapeutic vaccine based on the
myvac® platform) as well as two oncolytic viruses (TG6002 for the
treatment of solid tumors, and BT-001, the first oncolytic virus
based on the Invir.IO™ platform).
With Transgene’s myvac® platform, therapeutic vaccination enters
the field of precision medicine with a novel immunotherapy that is
fully tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building
on its viral vector engineering expertise to design a new
generation of multifunctional oncolytic viruses. Transgene has an
ongoing Invir.IO™ collaboration with AstraZeneca.
Additional information about Transgene is available at:
www.transgene.fr
Follow us on Twitter: @TransgeneSA
Disclaimer
This press release contains forward-looking statements, which
are subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. The
occurrence of any of these risks could have a significant negative
outcome for the Company’s activities, perspectives, financial
situation, results, regulatory authorities’ agreement with
development phases, and development. The Company’s ability to
commercialize its products depends on but is not limited to the
following factors: positive pre-clinical data may not be predictive
of human clinical results, the success of clinical studies, the
ability to obtain financing and/or partnerships for product
manufacturing, development and commercialization, and marketing
approval by government regulatory authorities. For a discussion of
risks and uncertainties which could cause the Company’s actual
results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please
refer to the Risk Factors (“Facteurs de Risque”) section of the
Universal Registration Document, available on the AMF website
(http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made, and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220525005695/en/
Transgene: Lucie Larguier Director Corporate
Communications & IR +33 (0)3 88 27 91 04
investorrelations@transgene.fr
Media Transgene: MEDiSTRAVA Consulting David
Dible/Sylvie Berrebi +44 (0)203 928 6900
transgene@medistrava.com
Transgene (EU:TNG)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Transgene (EU:TNG)
Historical Stock Chart
Von Apr 2023 bis Apr 2024